Doherty K, Barry M, Marcano-Belisario J, Arnaud B, Morrison C, Car J, Doherty G. A mobile app for the self-report of psychological well-being during pregnancy (BrightSelf): qualitative design study. JMIR Ment Health. 2018 Nov 27;5(4):e10007. doi: 10.2196/10007
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Farreny A, Aguado J, Corbera S, Ochoa S, Huerta-Ramos E, Usall J. Baseline predictors for success following strategy-based cognitive remediation group training in schizophrenia. J Nerv Ment Dis. 2016 Aug;204(8):585-9. doi: 10.1097/NMD.0000000000000509
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Scott Graham R, Samsell BJ, Proffer A, Moore MA, Vega RA, Stary JM, Mathern B. Evaluation of glycerol-preserved bone allografts in cervical spine fusion: a prospective, randomized controlled trial. J Neurosurg Spine. 2015 Jan;22(1):1-10. doi: 10.3171/2014.9.SPINE131005
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Godding PR, McAnulty RD, Wittrock DA, Britt DM, Khansur T. Predictors of depression among male cancer patients. J Nerv Ment Dis. 1995 Feb 1;183(2):95-8.